RECRUITINGNA

Increasing Equity in Lung Cancer Screening

NCT06360822•Indiana University

Summary

The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key stakeholders; 2) pilot test the ED-LCS intervention evaluating the intervention efficacy, acceptability, and feasibility; and 3) provide an in-depth description of stakeholders' experiences with the ED-LCS intervention for future refinement.

Eligibility

Age

50 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•• Eligible for LCS (50-80 years old, smoked in past 15 years, and smoked at least 20 pack years)

Exclusion Criteria

•• Non-English/Spanish speaking
•* Decompensated psychiatric illness (suicidal, homicidal, psychosis). Will confirm with attending physicians at time of enrollment
•* Intoxicated with alcohol or drugs
•* Cannot provide reliable follow up contact information (cell phone)
•* Presenting to the ED with a life-threatening condition
•* Have received chest CT scan in past 12 months
•* Already enrolled in LCS
•* Hospice enrolled

Locations (1)

Eskenazi Health

Indianapolis, Indiana, United States

Key Dates

Start Date

December 1, 2023

Primary Completion Date

February 1, 2027

Completion Date

February 1, 2027

Last Updated

August 6, 2025

Enrollment

144

ESTIMATED participants

Conditions

Lung Cancer

Interventions

ED-LCS

BEHAVIORAL

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830

Lung AdenocarcinomaLung Large Cell Carcinoma+2 more

View study

RECRUITINGPHASE3

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 6, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGPHASE2